Investment Rating - The report maintains an "Outperform" rating for China Feihe [2][15]. Core Insights - The company reported total revenue of RMB 18.11 billion for 2025, a decrease of 12.7% year-over-year, and a net profit attributable to shareholders of RMB 1.94 billion, down 45.7% year-over-year, which fell short of market expectations [3][11]. - In the second half of 2025, revenue was RMB 8.96 billion, down 15.9% year-over-year, while net profit attributable to shareholders was RMB 940 million, down 44.6% year-over-year, although the decline in profits narrowed and operating margins improved [3][11]. - The company has proactively optimized channel inventory and controlled shipment schedules since May 2025, which, along with reduced government subsidies and impairment of biological assets, has placed short-term pressure on performance. However, following inventory destocking, fundamentals have strengthened, laying the foundation for profit recovery [3][11]. Revenue and Profit Forecast - Revenue is projected to be RMB 18.73 billion, RMB 19.47 billion, and RMB 20.36 billion for 2026, 2027, and 2028, respectively, with net profit attributable to shareholders expected to be RMB 2.41 billion, RMB 2.57 billion, and RMB 2.76 billion for the same years [5][15]. - The estimated diluted EPS for 2026, 2027, and 2028 is RMB 0.27, RMB 0.28, and RMB 0.30, respectively [5][15]. Business Structure and Growth - The business structure continues to optimize, with the core infant formula business generating RMB 15.87 billion, accounting for 87.6% of total revenue, and maintaining a market share of 19% [4][12]. - New product launches have shown promising results, with the newly launched products Jiecu and Qicu generating over RMB 69 million in revenue within a month of their release [4][12]. - The company is expanding its overseas business, with revenue from the U.S. and Canada reaching RMB 180 million and RMB 50 million, respectively, showing year-over-year growth of 11.7% and 23.3% [4][12]. Cost Management and Financial Health - The consolidated gross margin for the year was 65.0%, down 1.3 percentage points year-over-year, primarily due to an increased proportion of low-margin raw material powder revenue. However, the gross margin for infant formula powder improved to 73.5%, up 2.2 percentage points year-over-year [13]. - The company holds net cash of RMB 16.2 billion, indicating robust operating cash flow [13][14].

Investment Rating - The investment rating for China Feihe (06186.HK) is "Outperform" (maintained) [1] Core Insights - The company reported a revenue of 18.11 billion yuan in 2025, a decrease of 12.7% year-on-year, with a net profit of 1.94 billion yuan, down 45.7% year-on-year. The second half of 2025 saw a revenue of 8.96 billion yuan, down 15.9% year-on-year, and a net profit of 940 million yuan, down 44.6% year-on-year. The company expects a cumulative dividend payout ratio of 103% for 2025, corresponding to a dividend yield of 7.2% [3][4][6] Summary by Sections Financial Performance - In 2025, the company achieved a revenue of 181.1 billion yuan, a decline of 12.7% year-on-year, and a net profit of 19.4 billion yuan, down 45.7% year-on-year. The second half of 2025 recorded a revenue of 89.6 billion yuan, a decrease of 15.9% year-on-year, and a net profit of 9.4 billion yuan, down 44.6% year-on-year [3][4][6] - The gross margin for the second half of 2025 was 68.3%, an increase of 3.6 percentage points year-on-year, while the net profit margin was 10.5%, a decrease of 5.4 percentage points year-on-year [5] Revenue and Growth Drivers - The company is actively adjusting its main business to stabilize operations and is accelerating the growth of its second curve business. The revenue from infant formula and other dairy products in 2025 was 158.6 billion yuan, down 16.8% year-on-year, while nutritional supplements saw a revenue increase of 6.0% year-on-year [4] - The company launched upgraded products and new series, which are expected to contribute positively to revenue recovery in 2026, alongside the effects of fertility subsidies [4] Valuation Metrics - The estimated earnings per share (EPS) for 2026, 2027, and 2028 are projected to be 0.28, 0.29, and 0.30 yuan, respectively. The current stock price corresponds to a price-to-earnings (P/E) ratio of 9.7, 9.3, and 9.1 for the years 2026, 2027, and 2028 [3][6]

Investment Rating - The report maintains an "Accumulate" rating for China Feihe (6186.HK) with a current price of HKD 3.68 [1] Core Insights - In 2025, China Feihe achieved revenue of CNY 18.11 billion, a year-on-year decrease of 12.7%, and a net profit attributable to shareholders of CNY 1.94 billion, down 45.7% [4][5] - The infant formula business, which accounts for 88% of total revenue, faced pressure due to declining birth rates and increased competition, resulting in a revenue decline of 16.8% [5] - Despite challenges, the company remains a market leader with a 19% market share and high brand recognition [5] - New high-end products launched in 2025 have shown promising performance and are expected to contribute to revenue growth [5][8] - The company plans to maintain a high dividend policy, distributing no less than CNY 2 billion in dividends for 2025 [7] Financial Performance Summary - Revenue and profit forecasts for 2026-2028 have been adjusted downwards due to weak demand for infant formula, with projected net profits of CNY 2.29 billion in 2026 and CNY 2.45 billion in 2027 [8][11] - The overall gross margin for 2025 was 65.0%, a decrease of 1.3 percentage points, primarily due to an increase in low-margin raw material sales [7] - The company has a strong cash flow position, with operating cash flow projected to improve in the coming years [13] Market Expansion - In 2025, overseas revenue reached CNY 230 million, with significant growth in the Canadian market, where the company received its first foreign infant formula production license [8] - Plans for 2026 include entering the U.S. and Mexican markets, further expanding North American operations [8] Valuation and Earnings Forecast - The current stock price corresponds to a price-to-earnings ratio of 13x for 2026, 12x for 2027, and 11x for 2028, indicating a favorable valuation for a leading player in the domestic milk powder industry [8][11]

Core Viewpoint - The company reported a significant decline in revenue and net profit for the year 2025, primarily due to inventory clearance and reduced government subsidies, with expectations for recovery in 2026 driven by improved inventory management and potential positive impacts from fertility subsidies [1][2][3]. Financial Performance - In 2025, the company achieved revenue and net profit of 18.11 billion and 1.94 billion yuan, respectively, representing year-on-year declines of 12.7% and 45.7% [1]. - For the second half of 2025, revenue and net profit were 8.96 billion and 0.94 billion yuan, with declines of 15.9% and 44.6% year-on-year [1]. - The gross margin decreased by 1.3 percentage points to 65.0% for the full year, while the net profit margin fell by 6.5 percentage points to 10.7% [3]. Business Segment Performance - The dairy and nutrition products segment saw a revenue decline of 12.6% to 18.00 billion yuan, while the raw milk business experienced a 27.3% drop to 0.11 billion yuan in 2025 [2]. - The infant formula powder industry continued to face demand pressures, leading to a strategic inventory clearance by the company [2]. Regional Performance - In 2025, the company generated revenue of 17.88 billion yuan in mainland China, 0.18 billion yuan in the U.S., and 0.05 billion yuan in Canada, with year-on-year changes of -13.0%, +11.7%, and +23.3%, respectively [2]. Cost and Efficiency - The company's selling and administrative expense ratios increased significantly, with selling expenses rising by 4.9 percentage points to 39.5% and administrative expenses by 1.2 percentage points to 9.3% in 2025 [3]. - The company is focusing on enhancing channel inventory management and monitoring terminal pricing through digital store management and electronic fencing [2]. Future Outlook - The company anticipates a recovery in operations post-inventory clearance and expects the positive effects of fertility subsidies to materialize [1]. - Revenue forecasts for 2026 and 2027 have been adjusted to 18.84 billion and 19.51 billion yuan, reflecting a downward revision of 11% and 12% from previous estimates [3]. - The estimated earnings per share (EPS) for 2026, 2027, and 2028 are projected to be 0.31, 0.33, and 0.35 yuan, respectively, with a target price of 4.56 HKD based on a 13x price-to-earnings ratio for 2026 [3].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 4.56 [6][4]. Core Insights - The company reported a revenue of RMB 18.11 billion and a net profit attributable to the parent of RMB 1.94 billion for the year 2025, representing a year-on-year decline of 12.7% and 45.7% respectively. The performance was below expectations, as the prior forecast anticipated a revenue decline of only 4.0% and a net profit decline of 14.8% [1]. - The company is currently undergoing a channel inventory clearance, which has led to a temporary decline in revenue. However, it is expected that operations will return to normal after the inventory is cleared, with positive impacts anticipated from fertility subsidies [1][2]. - The gross margin for 2025 decreased by 1.3 percentage points to 65.0%, while the net profit margin fell by 6.5 percentage points to 10.7%. The decline in profitability was primarily due to reduced government subsidies and losses from inventory devaluation [3]. Revenue and Profitability - The revenue from the dairy products and nutrition segment decreased by 12.6% year-on-year to RMB 18.00 billion, while the raw milk business saw a decline of 27.3% to RMB 1.1 billion. The second half of 2025 also reflected a similar trend with a 15.9% and 9.7% decline respectively [2]. - The company’s gross margin for infant formula increased by 2.2 percentage points to 73.5% in 2025, but overall gross margin was impacted by a higher proportion of lower-margin products sold [3]. Forecast and Valuation - The revenue forecast for 2026 and 2027 has been adjusted downwards to RMB 18.84 billion and RMB 19.51 billion, reflecting a decrease of 11% and 12% from previous estimates. The expected net profit for these years is RMB 2.77 billion and RMB 3.01 billion, which is a reduction of 24% and 27% respectively [4]. - The estimated earnings per share (EPS) for 2026, 2027, and 2028 are projected to be RMB 0.31, RMB 0.33, and RMB 0.35 respectively, with a price-to-earnings (PE) ratio of 13x applied to the 2026 earnings to derive the target price [4][10].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.69 [6][4]. Core Insights - The company has shown robust performance driven by three main business segments: Adult Nutrition (ANC), Infant Nutrition (BNC), and Pet Nutrition (PNC). In 2025, the company achieved revenues of RMB 14.35 billion, net profit of RMB 200 million, and adjusted comparable net profit of RMB 660 million, reflecting year-on-year growth of 10.0%, a turnaround from loss, and an increase of 22.7% respectively [1][3]. - The company is expected to continue its steady growth in 2026, particularly in the ANC and PNC segments, with the infant formula business anticipated to recover further. The company is also focusing on debt reduction, having reduced total debt by over RMB 600 million during the year [1][4]. Summary by Relevant Sections Financial Performance - In 2025, the company reported a gross margin increase of 1.8 percentage points to 62.4%, driven by improved margins in the ANC and PNC segments and optimized procurement costs [3]. - The adjusted comparable EBITDA margin decreased by 0.7 percentage points to 14.3%, with variations across business segments: ANC at 19.9%, BNC at 11.4%, and PNC at 3.1% [3]. - The company ended 2025 with a cash balance exceeding RMB 1.7 billion and a net leverage ratio reduced from 3.99 times in 2024 to 3.45 times in 2025 [1][3]. Business Segment Performance - In 2025, the ANC segment revenue grew by 4.4%, with notable growth in the Chinese market at 13.3%, while the Australian and New Zealand market saw a decline of 21.8% due to a strategic reduction in purchasing business [2]. - The BNC segment showed significant recovery, with infant formula revenue increasing by 26.5% and probiotics and nutritional supplements for infants growing by 2.0% [2]. - The PNC segment reported a revenue increase of 8.7%, with growth in mainland China at 8.6% and North America at 7.8% [2]. Profit Forecast and Valuation - The profit forecast for 2026-2027 has been slightly raised, with expected net profits of RMB 730 million and RMB 860 million, representing increases of 13% and 16% respectively from previous estimates [4]. - The estimated EPS for 2026, 2027, and 2028 is projected at RMB 1.12, RMB 1.34, and RMB 1.48 respectively, with a reference PE ratio of 16x for 2026 [4][10].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.69 [6][4]. Core Views - The company has demonstrated stable operations driven by three main business segments: Adult Nutrition (ANC), Infant Nutrition (BNC), and Pet Nutrition (PNC). The revenue for 2025 is projected to be CNY 14.35 billion, with a year-on-year growth of 10.0% [1][2]. - The company has successfully turned around its net profit to CNY 2.0 billion in 2025, compared to a loss in the previous year, and adjusted net profit increased by 22.7% to CNY 6.6 billion [3][1]. - The company is expected to continue its steady growth in ANC and PNC segments, with the infant formula business anticipated to recover further [1][4]. Summary by Relevant Sections Financial Performance - In 2025, the company achieved revenues of CNY 14.35 billion, net profit of CNY 2.0 billion, and adjusted comparable net profit of CNY 6.6 billion, reflecting a year-on-year increase of 10.0%, a turnaround from loss, and a 22.7% increase respectively [1][3]. - The gross margin improved by 1.8 percentage points to 62.4% in 2025, driven by better margins in ANC and PNC segments [3]. - The company reduced its net leverage ratio from 3.99 times in 2024 to 3.45 times in 2025, with cash reserves exceeding CNY 1.7 billion at the end of 2025 [1][3]. Business Segment Performance - ANC revenue grew by 4.4% to CNY 69.5 billion, with strong performance in the Chinese market (+13.3%) but a decline in the Australian and New Zealand market (-21.8%) due to a strategic reduction in purchasing business [2]. - BNC revenue saw a significant recovery, with infant formula sales increasing by 26.5% and probiotics and nutritional supplements for infants growing by 2.0% [2]. - PNC revenue increased by 8.7%, with notable growth in the Chinese mainland (+8.6%) and North America (+7.8%) [2]. Profitability and Valuation - The adjusted comparable EBITDA margin decreased by 0.7 percentage points to 14.3% in 2025, with variations across business segments [3]. - The company has slightly raised its profit forecasts for 2026 and 2027, expecting net profits of CNY 7.3 billion and CNY 8.6 billion respectively, with an introduction of a 2028 forecast of CNY 9.6 billion [4]. - The target price of HKD 19.69 corresponds to a 16x PE ratio for 2026, reflecting a positive outlook based on comparable company valuations [4].

Core Viewpoint - Beiyinmei Co., Ltd. ("Beiyinmei", 002570.SZ), known as the "first stock of milk powder," is undergoing a potential change in control as its major shareholder, Zhejiang Xiaobei Demei Holdings Co., Ltd. ("Xiaobei Demei"), has signed a restructuring investment agreement with Jinhua Zhenhe Enterprise Management Partnership (Limited Partnership) ("Jinhua Zhenhe") and submitted a restructuring application to the Jinhua Intermediate People's Court on March 18, 2026 [3][4]. Group 1 - Xiaobei Demei cited liquidity issues and an inability to repay due debts as reasons for the restructuring, having previously submitted a pre-restructuring application in July 2025 [3][5]. - As of the announcement date, Xiaobei Demei holds approximately 130 million shares of Beiyinmei, accounting for 12.3% of the total share capital, with 98.9% of these shares pledged or frozen [3][5]. - Jinhua Zhenhe is set to invest approximately 860 million yuan and provide an additional 30 million yuan to help resolve related debts [3]. Group 2 - Beiyinmei was founded by Xie Hong in 1992 and was once a leading brand in the domestic milk powder market, achieving a market share of 10.8% in 2010 [4]. - After reaching a peak in performance in 2013, Beiyinmei's financial results began to decline, with revenues of 2.51 billion yuan, 2.53 billion yuan, and 2.77 billion yuan from 2022 to 2024, and net losses of 180 million yuan, 47.45 million yuan, and 100 million yuan during the same period [5]. - In the first three quarters of 2025, Beiyinmei's revenue decreased by 2.6% to 2.03 billion yuan, while net profit increased by 48.1% to 110 million yuan, indicating a stabilization in performance [5]. Group 3 - The restructuring plan aims to maintain stable operations for both Xiaobei Demei and Beiyinmei, support employee stock incentives, and optimize asset and debt structures [6]. - Beiyinmei asserts that it possesses independent business and operational capabilities, and changes in control will not significantly impact its daily operations [6]. - Industry analysts believe that if the debt issues of the major shareholder are resolved, it could significantly benefit Beiyinmei's future development [6].

Core Viewpoint - The Chinese dairy industry is at a critical transformation point, facing issues of overproduction of raw milk and high dependency on imported key raw materials, leading to an imbalance in the industry structure characterized by "low-end surplus and high-end shortage" [1][3][4]. Group 1: Industry Challenges - The dairy farming sector is projected to incur a cumulative income loss of 70 billion yuan from 2023 to 2025, with losses from fresh milk powder reaching 20 billion yuan [1]. - China is the largest importer of whey powder, accounting for 20% of global imports, with imports increasing from 376,000 tons in 2012 to 599,000 tons in 2022, reflecting an annual growth rate of approximately 4.8% [3]. - The current structure of the dairy industry shows that liquid milk accounts for 92.7% of production, while high-value products like cheese and butter make up less than 7.3%, indicating a significant imbalance [4]. Group 2: Need for Deep Processing - Developing key technologies and deep processing capabilities is essential to enhance the value of raw milk and optimize product structure, addressing the overproduction issue [4][5]. - Deep processing serves as a "reservoir" to regulate raw milk production and can significantly improve the overall utilization efficiency of raw materials, breaking the long-standing dependency on imports [5]. - Companies like Yili and Mengniu are making strides in deep processing, with Yili achieving over 90% retention of lactoferrin in milk and Mengniu launching high-value products like mascarpone cheese [6][8]. Group 3: Regulatory and Standardization Issues - The development of high-value functional raw materials is hindered by outdated regulations and standards, which restrict innovation and application of new technologies [8][9]. - Current regulations only allow the use of raw milk for deep processing, limiting the practical application of advanced extraction technologies [8]. - There is a growing global demand for high-quality proteins related to adult health, but domestic companies face challenges in scaling up production due to limited raw material types [8][9]. Group 4: Recommendations for Improvement - It is suggested to adjust and improve relevant laws and regulations to support the rapid development of dairy deep processing technologies while ensuring strict oversight of infant formula production [9][10]. - Establishing a comprehensive support system for the entire dairy supply chain, including the construction of processing parks and digital transformation, is recommended to enhance industry resilience [13]. - A focus on cultivating a skilled workforce in core R&D and engineering is essential for driving high-quality development in the dairy sector [11].

Core Insights - The core ingredients such as whey protein and lactoferrin are essential for infant formula and functional foods, but the industry heavily relies on imports, putting the domestic sector in a passive position [1] - The chairman of China Feihe, Leng Youbin, suggests enhancing core technology and deep processing to increase the added value of raw milk and optimize product structure, focusing on high-value products to promote the transformation and high-quality development of the dairy industry [1] Industry Structure - There is a significant imbalance in China's dairy product industry structure, with liquid milk accounting for 92.7% of the market, while high-value products like cheese and butter make up less than 7.3%, contrasting with developed countries like the Netherlands and France, where the ratio is approximately 5:5 [1] - The urgent need for structural upgrades and extending the value chain in the dairy industry is emphasized [1] Policy Recommendations - Leng Youbin recommends increasing policy support, improving regulations, assessment systems, and testing technologies, and enhancing professional talent training [2] - A target of over 60% domestic production rate for core ingredients like whey protein is suggested for the 14th Five-Year Plan to ensure a self-controlled supply chain in the dairy industry [2] - The need for timely adjustments to laws and regulations, industry standards, and approval processes for new technologies and products in dairy processing is highlighted [2] Talent Development - The dairy deep processing sector is identified as a multidisciplinary frontier with a shortage of specialized talent [2] - A proposal to cultivate over a thousand internationally competitive core R&D and engineering talents through interdisciplinary training and curriculum innovation is made to support high-quality development in the dairy industry [2]